Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Quinapril hydrochloride
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

82586-55-8

82586-55-8 structure

Name: Quinapril hydrochloride
Chemical Name: quinapril hydrochloride
CAS Number: 82586-55-8
Molecular Formula: C₂₅H₃₁ClN₂O₅
Molecular Weight: 474.977
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-07-04 21:36:40
Modify Date: 2026-08-02 19:17:31
Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.Target: ACEQuinapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril is now firmly established as an effective and well tolerated ACE inhibitor for the treatment of patients with hypertension and congestive heart failure. Quinapril 40 mg/day also significantly reduced the incidence of ischaemic events in patients undergoing CABG in one study [1, 2]. An overview of 32 clinical trials of ACE inhibitors in heart failure showed that no significant heterogeneity in mortality was found among enalapril, ramipril, quinapril, captopril, lisinopril, benazepril, perindopril and cilazapril. Initiation of therapy with captopril, ramipril, and trandolapril at least 3 days after an acute MI resulted in all-cause mortality risk reductions of 18 to 27% [3].

Name	quinapril hydrochloride
Synonyms	(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride Acuitel Quinapril HydrochlorideQ: What is Quinapril Hydrochloride Q: What is the CAS Number of Quinapril Hydrochloride Q: What is the storage condition of Quinapril Hydrochloride Q: What e the applications of Quinapril Hydrochloride 3-Isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)-, hydrochloride (1:1) Acequin Quinapril for system suitability quinapril HCl QuinaprilHclC25H30N205.HC1 Korectic Acupril Acuprel QUINAPRIL HCL Nipshin (3S)-2-[(2S)-2-{[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride ccupril QUINAPRIL HYDROCHLORIDE, RELATED COMPOUND B3-ISOQUINOLINECBOXYLIC ACID, 2-[2-[(1-CBOXY-3-PHENYLPROPYL)AMINO]-1-OXOPROPYL]-1,2,3,4-TETRAHYDRO-,[3S-[2[R(R)],3R]]- STANDD ACCUPRIN 3-isoquinolinecarboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, (3S)-, monohydrochloride ACCUPRIL monohydrochloride,(3s-(2(r(r)),3r))-henylpropyl)amino)-1-oxopropyl) Quinapril Hydrochloride (3S)-2-{N-[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride (1:1) MFCD00889215 (S)-2-[(S)-N-[(S)-1-Cboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-3-isoquinolinecboxylic acid, 1-ethyl ester, monohydrochloride Acrylamide Impurity 5 QUINAPRIL HYDROCHLORIDE, RELATED COMPOUND A ETHYL[3S-[2(R),3A,11A BETA]]-1,3,4,6,11,11A-HEXAHYDRO-3-METHYL-1,4-DIOXO-ALPHA-(2-PHENYLETHYL)-2H-PYRAZINO[1,2-B]ISOQUINOLINE-2-ACETATE STANDD (3S)-2-[(2S)-2-[[(1S)-1-(ETHOXYCBONYL)-3-PHENYLPROPYL]AMINO]-1-OXOPROPYL]-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECBOXYLIC ACID HYDROCHLORIDE acide (3S)-2-[(2S)-2-{[(1S)-1-(éthoxycarbonyl)-3-phénylpropyl]amino}propanoyl]-1,2,3,4-tétrahydroisoquinoléine-3-carboxylique chlorhydrate (3S-(2(R(R)),3R))-2-(2-((1-(Ethoxycbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecboxylic acid monohydrochloride (3S)-2-{N-[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]-L-alanyl}-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride (1:1) Quinapril hydrochloride //BP Quinapril hydrochloride CRS 2-<<1-ethoxycarbonyl)-3-phenylpropyl>amino>-1-oxopropyl>-1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid monohydrochloride (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-cboxylic acid hydrochloride 3-isoquinolinecboxylicacid,1,2,3,4-tetrahydro-2-(2-((1-(ethoxycbonyl)-3-p Quinapril HCl - Bio-X PD-109452-2 Quinapril hydrochloride (Accupril) Quinapril for peak identification CRS (3S)-2-[(2S)-2-[[(1S)-1-cbethoxy-3-phenyl-propyl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride (S)-2-(((S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-cboxylic acid hydrochloride CI-906, PD-109452-2, Accupril, Accuprin, Accupro ACCUPRO Korec WIDELY Quinapril HCL Quinapril (hydrochloride) (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenyl-butan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-cboxylic acid hydrochloride Accupron (3S)-2-[(2S)-2-{[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino}propanoyl]-1,2,3,4-tetrahydroisochinolin-3-carbonsäurehydrochlorid 3-Isoquinolinecboxylic acid, 2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, monohydrochloride, (3S)- (9CI) Quinazil Quinapril for system suitability CRS Quinapril HCl (CI-906) Quinapril for peak identification Conan Quinapril HCl API (3S)-2-{N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride Quinapril hydrochloride, ACE inhibitor Quinapril hydrochloride, 10 mM in DMSO Quinapril hydrochlor Quinapril hydrochloride in methanol 3-Isoquinolinecboxylic acid, 2-[2-[[1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, monohydrochloride, [3S-[2[R(R)],3R*]] CI-906 Quinapril hydrochloride, >= (3S)-2-[(2S)-2-[[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecboxylic acid, hydrochloride (1:1) Acequide QuinaprilHydrochloride

Description	Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.Target: ACEQuinapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of hypertension and congestive heart failure. Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril is now firmly established as an effective and well tolerated ACE inhibitor for the treatment of patients with hypertension and congestive heart failure. Quinapril 40 mg/day also significantly reduced the incidence of ischaemic events in patients undergoing CABG in one study [1, 2]. An overview of 32 clinical trials of ACE inhibitors in heart failure showed that no significant heterogeneity in mortality was found among enalapril, ramipril, quinapril, captopril, lisinopril, benazepril, perindopril and cilazapril. Initiation of therapy with captopril, ramipril, and trandolapril at least 3 days after an acute MI resulted in all-cause mortality risk reductions of 18 to 27% [3].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE) Research Areas >> Cardiovascular Disease
References	[1]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24. [2]. Culy, C.R. and B. Jarvis, Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs, 2002. 62(2): p. 339-85. [3]. Klutchko, S., et al., Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem, 1986. 29(10): p. 1953-61.

Boiling Point	662ºC at 760 mmHg
Melting Point	120-130ºC
Molecular Formula	C₂₅H₃₁ClN₂O₅
Molecular Weight	474.977
Flash Point	354.1ºC
Exact Mass	474.192139
PSA	95.94000
LogP	3.69790
Storage condition	2-8°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: NW7176000

CHEMICAL NAME :: 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-(2-((1-(ethoxycarbonyl)-3-phenyl propyl) amino)-1-oxopropyl)-, monohydrochloride, (3S-(2(R*(R*)),3R*))-

CAS REGISTRY NUMBER :: 82586-55-8

LAST UPDATED :: 199612

DATA ITEMS CITED :: 10

MOLECULAR FORMULA :: C25-H30-N2-O5.Cl-H

MOLECULAR WEIGHT :: 475.03

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3541 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANGIAB Angiology. (Angiology Research Found., Inc., 320 Northern Blvd., Great Neck, NY 11021) V.1- 1950- Volume(issue)/page/year: 40,335,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 107 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANGIAB Angiology. (Angiology Research Found., Inc., 320 Northern Blvd., Great Neck, NY 11021) V.1- 1950- Volume(issue)/page/year: 40,335,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1739 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANGIAB Angiology. (Angiology Research Found., Inc., 320 Northern Blvd., Great Neck, NY 11021) V.1- 1950- Volume(issue)/page/year: 40,335,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 504 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ANGIAB Angiology. (Angiology Research Found., Inc., 320 Northern Blvd., Great Neck, NY 11021) V.1- 1950- Volume(issue)/page/year: 40,335,1989

TYPE OF TEST :: LD - Lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,740,1995 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3640 mg/kg/52W-I

TOXIC EFFECTS :: Blood - other changes Nutritional and Gross Metabolic - changes in sodium Related to Chronic Data - death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 46,121,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 3650 mg/kg/1Y-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - other changes

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 46,139,1993 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 700 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception lactating female 1-21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 17,684,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 330 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 46,197,1993

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 78 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 1-21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 49,465,1995

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes	Xi
Safety Phrases	22-24/25
RIDADR	NONH for all modes of transport
RTECS	NW7176000

82586-54-7

82586-55-8

Literature: WO2004/54980 A1, ; Page 25;13;16 ;

82586-56-9

82586-55-8

115-11-7

Literature: US2004/192613 A1, ; Page/Page column 5 ;

Precursor 2
82586-54-7 82586-56-9
DownStream 4
85441-61-8 103733-49-9 82768-85-2 103733-35-3

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1426806-63-4	1574398-89-2
1344920-15-5	1574296-38-0
1574400-24-0	1574353-65-3
1574303-44-8	1574398-94-9
1574296-97-1	1574292-27-5